Emergent renal and hepatic dysfunction (dys) in a real-world cohort of advanced melanoma (aMel) patients (pts) receiving first line (1L) immune checkpoint inhibitors (ICIs).

e21582Background: ICI trials report varying rates of renal and hepatic toxicity. We evaluated a real-world cohort of aMel pts with normal baseline renal and hepatic labs to identify changes consist...